Experience with Empirical Treatment of Severe Acute Respiratory Syndrome Due to Coronavirus, Genotype IV

Foreign experience with empirical management of severe acute respiratory syndrome (SARS) due to coronavirus, genotype IV is described. It is indicated that the data on the efficacy of ribavirin with respect to SARS in the patients are contradictory. The efficacy of two chemotherapeutics, i. e. lopin...

Full description

Saved in:
Bibliographic Details
Main Authors: V. N. Shchukina, S. Ya. Loginova, S. V. Borisevich, V. P. Bondarev
Format: Article
Language:Russian
Published: LLC "Publishing House OKI" 2020-05-01
Series:Антибиотики и Химиотерапия
Subjects:
Online Access:https://www.antibiotics-chemotherapy.ru/jour/article/view/391
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849244584472739840
author V. N. Shchukina
S. Ya. Loginova
S. V. Borisevich
V. P. Bondarev
author_facet V. N. Shchukina
S. Ya. Loginova
S. V. Borisevich
V. P. Bondarev
author_sort V. N. Shchukina
collection DOAJ
description Foreign experience with empirical management of severe acute respiratory syndrome (SARS) due to coronavirus, genotype IV is described. It is indicated that the data on the efficacy of ribavirin with respect to SARS in the patients are contradictory. The efficacy of two chemotherapeutics, i. e. lopinavir and ritonavir used in the SARS foci is confirmed. The drugs are at present applicable all over the world in retrovirus therapy of HIV infected subjects. The search for efficient Russian unspecific medicines for control of SARS is actual.
format Article
id doaj-art-0c16e8d1224f4af6985ee82061cf6e23
institution Kabale University
issn 0235-2990
language Russian
publishDate 2020-05-01
publisher LLC "Publishing House OKI"
record_format Article
series Антибиотики и Химиотерапия
spelling doaj-art-0c16e8d1224f4af6985ee82061cf6e232025-08-20T03:59:08ZrusLLC "Publishing House OKI"Антибиотики и Химиотерапия0235-29902020-05-01567-84246390Experience with Empirical Treatment of Severe Acute Respiratory Syndrome Due to Coronavirus, Genotype IVV. N. Shchukina0S. Ya. Loginova1S. V. Borisevich2V. P. Bondarev3Филиал федерального государственного учреждения «48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации - «Вирусологический центр»Филиал федерального государственного учреждения «48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации - «Вирусологический центр»Филиал федерального государственного учреждения «48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации - «Вирусологический центр»Филиал федерального государственного учреждения «48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации - «Вирусологический центр»Foreign experience with empirical management of severe acute respiratory syndrome (SARS) due to coronavirus, genotype IV is described. It is indicated that the data on the efficacy of ribavirin with respect to SARS in the patients are contradictory. The efficacy of two chemotherapeutics, i. e. lopinavir and ritonavir used in the SARS foci is confirmed. The drugs are at present applicable all over the world in retrovirus therapy of HIV infected subjects. The search for efficient Russian unspecific medicines for control of SARS is actual.https://www.antibiotics-chemotherapy.ru/jour/article/view/391severe acute respiratory syndromeantiviral activitycoronavirus infectionchemotherapyribavirinlopinavirritonavir
spellingShingle V. N. Shchukina
S. Ya. Loginova
S. V. Borisevich
V. P. Bondarev
Experience with Empirical Treatment of Severe Acute Respiratory Syndrome Due to Coronavirus, Genotype IV
Антибиотики и Химиотерапия
severe acute respiratory syndrome
antiviral activity
coronavirus infection
chemotherapy
ribavirin
lopinavir
ritonavir
title Experience with Empirical Treatment of Severe Acute Respiratory Syndrome Due to Coronavirus, Genotype IV
title_full Experience with Empirical Treatment of Severe Acute Respiratory Syndrome Due to Coronavirus, Genotype IV
title_fullStr Experience with Empirical Treatment of Severe Acute Respiratory Syndrome Due to Coronavirus, Genotype IV
title_full_unstemmed Experience with Empirical Treatment of Severe Acute Respiratory Syndrome Due to Coronavirus, Genotype IV
title_short Experience with Empirical Treatment of Severe Acute Respiratory Syndrome Due to Coronavirus, Genotype IV
title_sort experience with empirical treatment of severe acute respiratory syndrome due to coronavirus genotype iv
topic severe acute respiratory syndrome
antiviral activity
coronavirus infection
chemotherapy
ribavirin
lopinavir
ritonavir
url https://www.antibiotics-chemotherapy.ru/jour/article/view/391
work_keys_str_mv AT vnshchukina experiencewithempiricaltreatmentofsevereacuterespiratorysyndromeduetocoronavirusgenotypeiv
AT syaloginova experiencewithempiricaltreatmentofsevereacuterespiratorysyndromeduetocoronavirusgenotypeiv
AT svborisevich experiencewithempiricaltreatmentofsevereacuterespiratorysyndromeduetocoronavirusgenotypeiv
AT vpbondarev experiencewithempiricaltreatmentofsevereacuterespiratorysyndromeduetocoronavirusgenotypeiv